*October 2023* Sandip P. Patel, MD discusses treatment options available for patients with EGFR-mutant NSCLC who progress on EGFR TKIs and platinum-based chemotherapy. Watch video here.
laurabbook@gmail.comDecember 27, 2023
Recent News & Research
*October 2023* Take home message: Comparison Dato-DXd, a novel TROP2-directed antibody-drug conjugate, to docetaxel in pretreated advanced/metastatic non-small cell lung cancer (NSCLC) patients, revealing significantly improved progression-free survival with Dato-DXd, especially in non-squamous histology patients, while demonstrating a manageable safety profile and ongoing evaluation of overall survival. (From OncoAlert) The Trop-2…
laurabbook@gmail.comDecember 27, 2023
*October 2023* PURPOSE In the treatment of non-small cell lung cancer (NSCLC) with a driver mutation, the role of anti-PD-(L)1 antibody following tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase 3 study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel and carboplatin (ABCP) in EGFR or ALK-mutated NSCLC that progressed…
laurabbook@gmail.comDecember 24, 2023
*October 2023* The European Commission (EC) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.1 The regulatory decision was supported by data from the phase…
laurabbook@gmail.comDecember 24, 2023
*October 2023* Take home message: Amivantamab in combination with chemotherapy showed significantly improved PFS and a higher response rate compared to chemotherapy alone in treatment-naive patients with advanced non-small-cell lung cancer harboring EGFR exon 20 insertions, demonstrating its efficacy as a first-line treatment. The phase 3 PAPILLON trial (NCT04538664) resulted in…
laurabbook@gmail.comDecember 24, 2023
*October 2023* Osimertinib (Tagrisso) plus chemotherapy reduced the risk of central nervous system (CNS) disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer (NSCLC) who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial (NCT04035486) presented…
laurabbook@gmail.comDecember 24, 2023
*October 2023* Take home message: In 1L setting, combo of Amivantamab (ami), an EGFR-MET bispecific antibody, and Lazertinib (laz), a CNS-penetrant 3rd-generation EGFR TKI, was evaluated against Osimertinib (osi) in the MARIPOSA study (NCT04487080) for treatment-naïve, EGFR-mutated locally advanced or metastatic NSCLC. After a median follow-up of 22.0 months, ami+laz…
laurabbook@gmail.comDecember 24, 2023
*October 2023* by Juanita Segura Living with lung cancer is rough. Many look at me and tell me, “Juanita, you look so good,” or “You look so well.” But they don’t know what I’m going through mentally. Yes, we try to stay positive and do positive things, but that’s a chore…
laurabbook@gmail.comDecember 24, 2023
*November 2023* This month, we are honored to feature Dr. Christine Bestvina, Assistant Professor at the University of Chicago Medicine Comprehensive Cancer Center, specializing in thoracic oncology. Dr. Bestvina has been connected with the EGFR Resisters since she was a fellow at University of Chicago! She participated in the first…
laurabbook@gmail.comDecember 24, 2023
*November 2023* WASHINGTON, DC (November 1, 2023) – LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is thrilled to announce the recipients of the EGFR Resisters/LUNGevity Research Award for EGFR-Positive Lung Cancer. EGFR Resisters, a vibrant patient-led community advocating for improved treatment options for patients with EGFR-positive lung cancer,…
laurabbook@gmail.comDecember 24, 2023
